Literature DB >> 4010869

Overview on pharmacokinetics of nimodipine in healthy volunteers and in patients with subarachnoid hemorrhage.

K D Rämsch, G Ahr, D Tettenborn, L M Auer.   

Abstract

The pharmacokinetics of Nimodipine were studied in healthy volunteers and in patients with subarachnoid hemorrhage (SAH) following cerebral aneurysm rupture. Nimodipine was absorbed rapidly. After an oral dose of 120 mg an average maximal plasma concentration 106 micrograms/l was recorded 45 to 60 minutes later. During a 7-day oral therapy with 40 mg t.i.d. no accumulation or change in the absorption or elimination kinetics occurred. After i.v. administration a biphasic elimination with half lives of 7 min and 1 hour was observed. In patients with subarachnoid hemorrhage receiving a continuous infusion of 2 mg/hour the mean nimodipine plasma concentrations ranged between 36 and 72 micrograms/l. Subsequent oral dose of 60 mg q.i.d. to the same patients resulted in concentrations ranging between 17 to 42 micrograms/l on the average one hour after the dosage. Mean cerebrospinal fluid (CSF) levels amounted to 0.3 +/- 0.2 microgram/l in patients whose mean plasma concentrations were 76.9 +/- 34.0 micrograms/l.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4010869     DOI: 10.1055/s-2008-1054107

Source DB:  PubMed          Journal:  Neurochirurgia (Stuttg)        ISSN: 0028-3819


  21 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of calcium antagonists. An update.

Authors:  J G Kelly; K O'Malley
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  An experimental study of the effect of nimodipine in primate subarachnoid haemorrhage.

Authors:  N W Dorsch; N M Branston; R J Harris; P Bentivoglio; L Symon
Journal:  Acta Neurochir (Wien)       Date:  1989       Impact factor: 2.216

4.  Plasma concentrations and haemodynamic effects of nimodipine in patients resuscitated after cardiac arrest.

Authors:  L P Huyghens; W A Buylaert; L Corne; M T Rosseel; M G Bogaert
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Investigation of nimodipine pharmacokinetics in Chinese patients with acute subarachnoid haemorrhage.

Authors:  C R Kumana; M Kou; Y L Yu; K Y Fong; C F Fung; C M Chang; W Mück; I J Lauder
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 6.  Nimodipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in cerebrovascular disease.

Authors:  M S Langley; E M Sorkin
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

7.  Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E Vinge; K E Andersson; L Brandt; B Ljunggren; L G Nilsson; S Rosendal-Helgesen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

8.  Inhibition of cerebral vasoconstriction by dantrolene and nimodipine.

Authors:  Salvatore Salomone; Guray Soydan; Michael A Moskowitz; John Randall Sims
Journal:  Neurocrit Care       Date:  2008-10-16       Impact factor: 3.210

9.  Nimodipine disposition and haemodynamic effects in patients with cirrhosis and age-matched controls.

Authors:  F M Gengo; S C Fagan; G Krol; H Bernhard
Journal:  Br J Clin Pharmacol       Date:  1987-01       Impact factor: 4.335

10.  Differential effects of valproic acid and enzyme-inducing anticonvulsants on nimodipine pharmacokinetics in epileptic patients.

Authors:  A Tartara; C A Galimberti; R Manni; L Parietti; C Zucca; H Baasch; L Caresia; W Mück; N Barzaghi; G Gatti
Journal:  Br J Clin Pharmacol       Date:  1991-09       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.